ライフサイエンスコーパス: multidrug-resistant

1 agnosed with a second episode of TB that was multidrug resistant.

2 ficult to treat, as K. pneumoniae has become multidrug resistant.

3 ogens were identified, none were found to be multidrug resistant.

4 rains that are livestock-associated (LA) and multidrug-resistant.

5 We have previously observed that multidrug-resistant 2 (Mdr2(-/-) ) double knockout (DKO)

6 A high proportion were found to be multidrug-resistant (34/178; 19.1%), established through

7 estigated draft genomes of phage susceptible multidrug resistant A. baumannii strains from Thailand.

8 Indeed, multidrug-resistant A. baumannii is a major cause of hos

9 f oxyR in both antimicrobial-susceptible and multidrug-resistant A. baumannii strains impairs growth

10 deaths were hospital acquired, mainly due to multidrug-resistant Acinetobacter baumannii (52.2%), Kle

11 rently in development as an oral therapy for multidrug resistant and carbapenem-resistant Enterobacte

12 monas aeruginosa infections are increasingly multidrug resistant and cause healthcare-associated pneu

13 e countries, it has since the 1990s reported multidrug resistant and extensively drug resistant (XDR)

14 have recently been approved for treatment of multidrug-resistant and extensively drug-resistant (XDR)

15 ith broad-spectrum in vitro activity against multidrug-resistant and extensively drug-resistant bacte

16 strain mc(2)6230 and also against a panel of multidrug-resistant and extensively drug-resistant clini

17 are under threat because of the emergence of multidrug-resistant and extensively drug-resistant tuber

18 ibits in vivo efficacy against a challenging multidrug-resistant and vancomycin-resistant S. aureus s

19 The spread of multidrug resistant bacteria has become a global concern

20 Infections caused by multidrug resistant bacteria represent a therapeutic cha

21 e, which has contributed to the emergence of multidrug resistant bacteria worldwide.

22 cs, and are a major disseminating source for multidrug resistant bacteria.

23 inhibitory effect targeting a wide range of multidrug resistant bacteria.

24 Infections by multidrug-resistant bacteria (MDRB) remain a leading cau

25 Rationale: Infections caused by multidrug-resistant bacteria are a major clinical challe

26 he surface of the ETT and the development of multidrug-resistant bacteria are considered the primary

27 Since the emergence of deadly pathogens and multidrug-resistant bacteria at an alarmingly increased

28 f the most important and emergent classes of multidrug-resistant bacteria is extended-spectrum beta-l

29 Multidrug-resistant bacteria pose a serious health threa

30 ing high in vitro potency against pathogenic multidrug-resistant bacteria, further development of sev

31 ive MAC transfer leads to the elimination of multidrug-resistant bacteria, including Staphylococcus a

32 ntibiotic therapy, chronic colonization with multidrug-resistant bacteria, or moribund status were ex

33 ups of patients, such as those infected with multidrug-resistant bacteria, who were not included in e

34 that they kill clinical isolates of several multidrug-resistant bacteria-including those from the ge

35 vides an alternative strategy for overcoming multidrug-resistant bacteria-induced sepsis and opens up

36 s (MACs) can be applied for the treatment of multidrug-resistant bacteria-induced sepsis in mice with

37 n proposed as an alternative therapy against multidrug-resistant bacteria.

38 high-school students in the investigation of multidrug-resistant bacteria.

39 priority to combat the increasing spread of multidrug-resistant bacteria.

40 s and contributes to increased prevalence of multidrug-resistant bacteria.

41 ion as new drugs or drug adjuvants to combat multidrug-resistant bacteria.

42 ecognized dominant role of hospital-acquired multidrug-resistant bacterial infections as the leading

43 noglycoside antibiotics for the treatment of multidrug-resistant bacterial infections, particularly t

44 y tract and respiratory infections caused by multidrug-resistant bacterial pathogens, a serious publi

45 ntibacterial drugs to combat infections with multidrug-resistant bacterial pathogens.

46 s in the 2016 to 2018 multistate outbreak of multidrug-resistant C. jejuni Here, we aimed to elucidat

47 report the isolation of 2 clonal lineages of multidrug-resistant Campylobacter coli from MSM in Seatt

48 ergistic therapeutic activity is achieved in multidrug resistant cancer cells and a tumor model.

49 e compounds for the selective elimination of multidrug resistant cancer cells, setting the stage for

50 017, a patient presented colonization with a multidrug-resistant, carbapenemase (KPC-3)-producing Kle

51 previously reported that some, but not all, multidrug-resistant cells that overexpressed various dru

52 ding pocket substitution discovered within a multidrug resistant clinical isolate modifies the plasti

53 scherichia coli ST131 is a globally dominant multidrug resistant clone associated with high rates of

54 sal drug-susceptible bacteria to evolve into multidrug-resistant clones that are able to successfully

55 A multidrug-resistant co-lineage of Plasmodium falciparum

56 port the first case of belatacept-associated multidrug-resistant Cytomegalovirus retinitis in a kidne

57 were at least two times more effective on a multidrug-resistant derivative than on the parental cell

58 ce of antimicrobial resistant phenotypes and multidrug-resistant E coli carriage in urban wildlife is

59 amined factors associated with the spread of multidrug-resistant E. coli phenotypes responsible for d

60 antibiotic resistome, prolonged carriage of multidrug-resistant Enterobacteriaceae and distinct anti

61 arenteral aminoglycoside developed to target multidrug-resistant Enterobacteriaceae.

62 (phages), that could be harnessed to combat multidrug-resistant enterococcal infections.

63 Multidrug-resistant Enterococcus faecalis, an opportunis

64 emergence across multiple US cities of a new multidrug-resistant Escherichia coli clone-sequence type

65 we measured the recombination parameters of multidrug-resistant Escherichia coli ST131.

66 ty to inhibit growth of clinical isolates of multidrug-resistant ESKAPE pathogens.

67 be cyphomycin, a new molecule active against multidrug resistant fungal pathogens.

68 Candida auris is an emerging multidrug-resistant fungal pathogen that has been associ

69 Candida auris, a multidrug-resistant fungal pathogen, is responsible for

70 gainst strains of Candida auris, an emerging multidrug-resistant fungus that presents a serious globa

71 nterventions and includes C. auris, a highly multidrug-resistant fungus.

72 concern with respect to the transmission of multidrug-resistant gastrointestinal pathogens and the r

73 in both species and were commonly present in multidrug-resistant genomic islands (GIs), often located

74 -Leg5,7Ac(2) was efficacious against several multidrug-resistant gonococci in mice with a humanized s

75 Novel therapies to counteract multidrug-resistant gonorrhea are urgently needed.

76 immunotherapies against the global threat of multidrug-resistant gonorrhea.

77 address the critical medical need created by multidrug resistant Gram-negative bacteria.

78 Multidrug resistant Gram-negative bacterial infections a

79 ibiotic for the treatment of a wide range of multidrug resistant Gram-negative bacterial infections,

80 last-resort antibiotic for the treatment of multidrug resistant Gram-negative bacterial infections.

81 Multidrug-resistant Gram-negative (GN) infections for wh

82 Patients with multidrug-resistant gram-negative bacilli (MDR-GNB), acc

83 vancomycin-resistant enterococci (P = .008), multidrug-resistant gram-negative bacteria (P = .016), o

84 the treatment of human infections caused by multidrug-resistant Gram-negative bacteria.

85 in antibiotics are a last-line treatment for multidrug-resistant Gram-negative bacteria.

86 or treatment of serious infections caused by multidrug-resistant gram-negative bacteria.

87 to have a wide spectrum of activity against multidrug-resistant Gram-negative bacteria; however, bre

88 baumannii is an opportunistic and frequently multidrug-resistant Gram-negative bacterial pathogen tha

89 Treatment of multidrug-resistant Gram-negative bacterial pathogens re

90 (polymyxin B and colistin) for treatment of multidrug-resistant Gram-negative infections, many clini

91 ycin-resistant Enterococcus spp. and several multidrug-resistant Gram-negative organisms.

92 oad in vitro spectrum of activity, including multidrug-resistant Gram-negative pathogens, and is bein

93 antimicrobials with potent activity against multidrug-resistant gram-negative pathogens, such as car

94 ed Mag(i+4)1,15(A9K,B21A,N22K,S23K) can kill multidrug-resistant Gram-negative pathogens, such as col

95 tibiotic of last resort for the treatment of multidrug-resistant Gram-positive bacterial infections.

96 23, was more potent than vancomycin against multidrug-resistant Gram-positive clinical isolates, inc

97 The cadasides inhibit the growth of multidrug-resistant Gram-positive pathogens by disruptin

98 pibrentasvir was also effective in clearing multidrug-resistant HCV replication in mice.

99 l in 23 countries, we enrolled patients with multidrug-resistant HIV-1 infection in two cohorts, acco

100 In patients with multidrug-resistant HIV-1 infection with limited therapy

101 cellent antiviral potency against a panel of multidrug-resistant HIV-1 strains, analogues with the po

102 avily treatment-experienced individuals with multidrug-resistant HIV-1.

103 spital outbreaks and the recent emergence of multidrug-resistant hypervirulent strains.

104 glycoside with bactericidal activity against multidrug-resistant (including carbapenem-resistant) Ent

105 t acquisitions of extensively drug-resistant/multidrug-resistant-inducing plasmids, probably facilita

106 are nosocomial pathogens frequently causing multidrug-resistant infections that are increasing at al

107 Pseudomonas aeruginosa causes severe multidrug-resistant infections that often lead to bacter

108 and are acutely vulnerable to the threat of multidrug-resistant infections.

109 ly, we identified several hundred genes in a multidrug-resistant isolate of Acinetobacter baumannii t

110 ollection of 197 P. aeruginosa that included multidrug-resistant isolates to determine whether 2 repr

111 flagged such as cross-resistance against the multidrug-resistant K1 strain, in vitro cytotoxicity, an

112 lo-beta-lactamase (NDM)-producing strains of multidrug-resistant Klebsiella pneumoniae are a global p

113 y drug-resistant Acinetobacter baumannii and multidrug-resistant Klebsiella pneumoniae was treated wi

114 We aimed to estimate the global burden of multidrug-resistant latent tuberculosis infection to inf

115 ug delivery system can precisely reverse the multidrug resistant leukemia phenotype based on preclini

116 nst CA-4-resistant colon-carcinoma cells and multidrug-resistant leukemia cells.

117 The well-described multidrug-resistant lineage is associated with high rate

118 RT) constitutes a promising target to combat multidrug-resistant malaria.

119 ROR1's potential as a therapeutic target for multidrug resistant malignancies.

120 e PostVac-II period; these isolates were all multidrug resistant (MDR) and were members of the Taiwan

121 Multidrug resistant (MDR) bacteria are a global threat w

122 iotemporal and phylogenetic relationships of multidrug resistant (MDR) bacteria on intensive care uni

123 s new avenues for diagnosis and treatment of multidrug resistant (MDR) bacterial infections.

124 Multidrug resistant (MDR) carbapenemase-producing (CP) K

125 study, we aimed to isolate and characterize multidrug resistant (MDR) E. coli in raw chicken meat sa

126 The multidrug resistant (MDR) opportunistic pathogen Klebsie

127 Multidrug resistant (MDR) strains of Acinetobacter bauma

128 s have risen sharply due to the emergence of multidrug resistant (MDR) strains of C. albicans and oth

129 effect on some enteric pathogens, including multidrug resistant (MDR) strains of Salmonella Typhimur

130 n half (53.8%; 242/450) of NTS isolates were multidrug resistant (MDR; resistant to >=3 antimicrobial

131 high rates of AMR, with 51.9% (28/54) being multidrug-resistant (MDR) and 53.6% of these (15/28) bei

132 We sequenced the whole genome of multidrug-resistant (MDR) and extensively drug-resistant

133 Multidrug-resistant (MDR) bacteria that are commonly ass

134 cular promise for preventing and controlling multidrug-resistant (MDR) bacterial infection via eradia

135 Emergence of multidrug-resistant (MDR) bacterial infections is a majo

136 cer by exploiting selective toxicity against multidrug-resistant (MDR) cancer.

137 With multidrug-resistant (MDR) Enterobacterales on the rise,

138 ctions caused by carbapenem-resistant and/or multidrug-resistant (MDR) Gram-negative bacteria in clin

139 blue light ([aBL] 405 nm wavelength) against multidrug-resistant (MDR) Gram-negative bacteria in vitr

140 Treatment options for multidrug-resistant (MDR) gram-negative infection are gr

141 new antibiotic classes with activity against multidrug-resistant (MDR) Gram-negative pathogens as the

142 The increasing level of multidrug-resistant (MDR) infections is a major cause of

143 We report a clonal outbreak of multidrug-resistant (MDR) Klebsiella variicola (sequence

144 tibiotic-tolerance and serves as a source of multidrug-resistant (MDR) mutations.

145 r latent tuberculosis contain drugs to which multidrug-resistant (MDR) Mycobacterium tuberculosis is

146 of new and 18% of recurrent cases of TB are multidrug-resistant (MDR) or rifampicin-resistant.

147 The emergence of multidrug-resistant (MDR) pathogens represents one of th

148 stance is lacking in LMICs, particularly for multidrug-resistant (MDR) pathogens.

149 imicrobial susceptibility was restored among multidrug-resistant (MDR) Pseudomonas aeruginosa.

150 Multidrug-resistant (MDR) Salmonella enterica has been d

151 erculosis (MIC = 4 ug/mL) and even against a multidrug-resistant (MDR) strain with nearly equal effec

152 Among 36 patients with multidrug-resistant (MDR) TB who had a sediment specimen

153 rthermore, 50% of the recovered strains were multidrug-resistant (MDR) to penicillins, cephalosporins

154 ctable (SLI) intolerance in the treatment of multidrug-resistant (MDR) tuberculosis, but the efficacy

155 ion between exposure to community venues and multidrug-resistant (MDR) tuberculosis.

156 not have tuberculosis) and patients who had multidrug-resistant (MDR) tuberculosis.

157 porin with activity against a broad array of multidrug-resistant (MDR), aerobic Gram-negative bacilli

158 dant as powerful antibacterial agent against multidrug-resistant (MDR), biofilm-forming E. coli.

159 We evaluated the accuracy of the BD MAX multidrug-resistant (MDR)-TB assay (BD MAX) in South Afr

160 association of MICs and treatment outcome in multidrug-resistant (MDR)-tuberculosis patients is uncle

161 gene acquisition, and two that were largely multidrug-resistant (MDR).

162 phenicol, and trimethoprim-sulfamethoxazole (multidrug-resistant [MDR]).

163 Multidrug-resistant Mycobacterium tuberculosis (MDR-TB)

164 sease (TB), with an increasing prevalence of multidrug-resistant Mycobacterium tuberculosis (MDR-TB)

165 rapeutic agents against the global threat of multidrug-resistant N. gonorrhoeae.

166 Multidrug-resistant Neisseria gonorrhoeae is a global he

167 cessus (Mab) is a rapidly growing species of multidrug-resistant nontuberculous mycobacteria that has

168 ins, which are responsible for the burden of multidrug-resistant nontyphoidal invasive disease in Afr

169 6.83%) staphylococci isolates recovered were multidrug resistant, of which 49 (8.17%) were mecA posit

170 an international collection of the emerging, multidrug-resistant, opportunistic pathogen Stenotrophom

171 f healthcare personnel hand contamination in multidrug-resistant organism (MDRO) transmission is impo

172 re used to compare changes in hospital-onset multidrug-resistant organism bloodstream infection (MDRO

173 Multidrug resistant organisms are a serious threat to hu

174 To address the growing threat of multidrug resistant organisms, policymakers are seeking

175 A-) Antibiotic Resistant Organisms (ARO) and Multidrug-Resistant Organisms (MDRO).

176 The extent to which donor multidrug-resistant organisms (MDROs) affect organ utili

177 peritonitis (SBP) in patients colonized with multidrug-resistant organisms (MDROs) is unknown.

178 Multidrug-resistant organisms (MDROs) spread between hos

179 nd effective strategy to prevent and control multidrug-resistant organisms (MDROs), and ESKAPE (Enter

180 health response to contain novel or targeted multidrug-resistant organisms (MDROs).

181 A) antibiotic-resistant organisms (AROs) and multidrug-resistant organisms (MDROs).

182 tion similar to one that was found to reduce multidrug-resistant organisms and bacteraemia in intensi

183 ling of healthcare-associated infections and multidrug-resistant organisms improves our understanding

184 lude inadequate source control, treatment of multidrug-resistant organisms, and pharmacokinetic alter

185 ulnerable to colonization and infection with multidrug-resistant organisms, including vancomycin-resi

186 To address the growing threat of multidrug-resistant organisms, policymakers are seeking

187 coccus aureus and cryptococcosis, as well as multidrug-resistant organisms.

188 nts to prevent or treat infections caused by multidrug-resistant organisms.

189 cope design flaws leading to transmission of multidrug-resistant organsisms persist despite recent in

190 rug-sensitive P. falciparum strain (3D7) and multidrug-resistant parasite (Dd2) in culture, with IC(5

191 se loci were in linkage equilibrium and that multidrug-resistant parasites have not expanded in this

192 modium falciparum blood-stage growth against multidrug-resistant parasites; (2) curative efficacy aft

193 Pseudomonas aeruginosa is an opportunistic multidrug-resistant pathogen and a common cause of infec

194 antibiotics, especially in the treatment of multidrug resistant pathogens.

195 penem-resistant Enterobacteriaceae (CRE) are multidrug-resistant pathogens for which new treatments a

196 is thought to contribute to the emergence of multidrug-resistant pathogens through horizontal gene tr

197 w several new antibiotics available to treat multidrug-resistant pathogens, and susceptibility testin

198 Infectious diseases due to multidrug-resistant pathogens, particularly carbapenem-r

199 tibacterial drugs that are effective against multidrug-resistant pathogens.

200 methyltransferases (Erms), rMtases found in multidrug-resistant pathogens.

201 el antibiotics are urgently needed to combat multidrug-resistant pathogens.

202 phages are of interest for phage therapy of multidrug-resistant pathogens.

203 asitic, and viral gastroenteritis, including multidrug-resistant pathogens.

204 in Ecc lineage 1, which had a higher rate of multidrug resistant phenotype (23/54 [43%]) relative to

205 s of antibiotics to 23S rRNA, resulting in a multidrug-resistant phenotype in bacteria expressing the

206 R genes and plasmids, including an identical multidrug-resistant plasmid isolated from both S. sonnei

207 uencing demonstrated global dissemination of multidrug-resistant plasmids across Shigella species and

208 The emergence and spread of multidrug-resistant Plasmodium falciparum in the Greater

209 Multidrug-resistant Plasmodium falciparum undermines the

210 e was a 26.0% (95% CI 17.7-33.0) decrease in multidrug-resistant pneumococcal colonization.

211 was released basolaterally, in part through Multidrug Resistant Protein transporters, taken up by fi

212 ing, we characterized genomic variability of multidrug-resistant Rhodococcus equi isolated from soil

213 rs with clinically-relevant activity against multidrug-resistant S. aureus.

214 derivative strain of the clinically isolated multidrug-resistant S. marcescens strain and found that

215 xposure and travel to describe the spread of multidrug-resistant Shigella lineages.

216 s, including globally distributed strains of multidrug-resistant Shigella species.

217 s, including globally-distributed strains of multidrug-resistant Shigella spp.

218 en, with most bacteria belonging to pandemic multidrug-resistant ST131-H30R or ST1193 clonal groups.

219 There was significantly higher proportion of multidrug resistant staphylococci (P = 0.0002) in East L

220 The alarming global rise in fatalities from multidrug-resistant Staphylococcus aureus (S. aureus) in

221 The multidrug-resistant Staphylococcus capitis NRCS-A clone

222 with single-colony phenotyping to identify a multidrug-resistant strain that had infected a patient f

223 enome-based prediction tools to identify the multidrug-resistant strain.

224 mportance of polymyxins and the emergence of multidrug resistant strains(5), our understanding of the

225 ainst many Gram-positive bacteria, including multidrug resistant strains.

226 Phylogenetics identified multidrug-resistant strains as being widely distributed

227 linical isolates of N. gonorrhoeae including multidrug-resistant strains at a concentration as low as

228 s previously reported for Shigella, specific multidrug-resistant strains of Campylobacter are circula

229 s previously reported for Shigella, specific multidrug-resistant strains of Campylobacter are circula

230 f healthcare-associated infections caused by multidrug-resistant strains producing extended-spectrum

231 at to public health due to the prevalence of multidrug-resistant strains, leading the World Health Or

232 ue to the increasingly frequent isolation of multidrug-resistant strains.

233 itis caused by Enterobacteriaceae, including multidrug-resistant strains.

234 losis strains, including clinically isolated multidrug-resistant strains.

235 ome active against pathogenic Clostridia and multidrug-resistant strains.

236 has been faced with an emerging threat from multidrug resistant TB (MDR-TB).

237 -TB treatment indicated an increased risk of multidrug-resistant TB (MDR-TB) emerging (8%), compared

238 is recommended in short-course regimens for multidrug-resistant TB (MDR-TB).

239 n a multicountry prospective cohort study of multidrug-resistant TB, we identified inhA, katG, and rp

240 ecommends shortcourse regimen (SCR) to treat multidrug resistant tuberculosis for patients with strai

241 two MTBC strains isolated from patients with multidrug resistant tuberculosis, representing an as-yet

242 ; 95% confidence interval, 0.18-0.48) and to multidrug-resistant tuberculosis (adjusted hazard ratio,

243 part of combination therapy for treatment of multidrug-resistant tuberculosis (MDR TB).

244 fumarate as part of combination therapy for multidrug-resistant tuberculosis (MDR TB).

245 manid are newly available drugs for treating multidrug-resistant tuberculosis (MDR TB); however, ther

246 mpared chest radiographic characteristics of multidrug-resistant tuberculosis (MDR-TB) and non-tuberc

247 Approximately 50% of multidrug-resistant tuberculosis (MDR-TB) and over 90% o

248 ousehold contacts (HHCs) of individuals with multidrug-resistant tuberculosis (MDR-TB) are at high ri

249 We assessed multidrug-resistant tuberculosis (MDR-TB) cases and thei

250 PZA resistance in multidrug-resistant tuberculosis (MDR-TB) is common and

251 Multidrug-resistant tuberculosis (MDR-TB) jeopardizes gl

252 ion (WHO) recommended a shorter (9-12 month) multidrug-resistant tuberculosis (MDR-TB) treatment regi

253 Linezolid is increasingly important for multidrug-resistant tuberculosis (MDR-TB) treatment.

254 tion as the preferred option in treatment of multidrug-resistant tuberculosis (MDR-TB) with long regi

255 manid are newly available drugs for treating multidrug-resistant tuberculosis (MDR-TB); however, ther

256 globally distributed and is associated with multidrug-resistant tuberculosis (TB) and treatment fail

257 Approximately 50% of multidrug-resistant tuberculosis and over 90% of extensi

258 327 patients were culture-positive for multidrug-resistant tuberculosis at baseline and compris

259 Understanding why some multidrug-resistant tuberculosis cases are not detected

260 on control measures, and active screening of multidrug-resistant tuberculosis contacts, with prophyla

261 The emergence and expansion of the multidrug-resistant tuberculosis epidemic is a threat to

262 rolonged (ie, 9-24 months) and patients with multidrug-resistant tuberculosis have less favourable ou

263 of the factors affecting the transmission of multidrug-resistant tuberculosis in HIV-endemic settings

264 eview what we know about the transmission of multidrug-resistant tuberculosis in settings with high b

265 may have a role in the management of latent multidrug-resistant tuberculosis infection.

266 18 years or older with confirmed or presumed multidrug-resistant tuberculosis initiating tuberculosis

267 A case of multidrug-resistant tuberculosis is presented.

268 Treatment for patients with multidrug-resistant tuberculosis is prolonged (ie, 9-24

269 Multidrug-resistant tuberculosis is the result of the se

270 We included 11 920 multidrug-resistant tuberculosis patients.

271 rug-resistant tuberculosis and patients with multidrug-resistant tuberculosis that was not responsive

272 d eligible adults (>18 years) with pulmonary multidrug-resistant tuberculosis to receive, in combinat

273 tching on age, sex, geographic site, year of multidrug-resistant tuberculosis treatment initiation, p

274 Individualised multidrug-resistant tuberculosis treatment with novel (e

275 s associated with increased mortality during multidrug-resistant tuberculosis treatment, but the exte

276 V-negative patients in terms of death during multidrug-resistant tuberculosis treatment, excluding th

277 ic nitroimidazole, was recently approved for multidrug-resistant tuberculosis treatment.

278 ations within lung cavities of patients with multidrug-resistant tuberculosis undergoing therapeutic

279 wed promising cure rates among patients with multidrug-resistant tuberculosis who received existing d

280 eport outcomes for a cohort of patients with multidrug-resistant tuberculosis who received high-dose

281 lly, 4.6% of patients with tuberculosis have multidrug-resistant tuberculosis, but in some areas, lik

282 cause many of these patients are at risk for multidrug-resistant tuberculosis, drug susceptibility te

283 , rifampicin and isoniazid), which is called multidrug-resistant tuberculosis, has continued to incre

284 ey had been exposed to an index patient with multidrug-resistant tuberculosis.

285 d mortality risk in HIV-positive adults with multidrug-resistant tuberculosis.

286 tly approved medication for the treatment of multidrug-resistant tuberculosis.

287 recently approved drugs for the treatment of multidrug-resistant tuberculosis.

288 gement and improve outcomes of patients with multidrug-resistant tuberculosis.

289 increased transmission and amplification of multidrug-resistant tuberculosis.

290 ds of death among HIV-positive patients with multidrug-resistant tuberculosis.

291 ive therapy on the contacts of patients with multidrug-resistant tuberculosis.Methods: In a prospecti

292 s, including lung metastatic tumors and even multidrug-resistant tumors.

293 There has been a recent expansion of multidrug-resistant typhoid fever globally.

294 entative strain of the globally disseminated multidrug-resistant UPEC ST131 clone, to zinc stress.

295 31-H30R subclone (H30) is a leading cause of multidrug-resistant urinary tract infection (UTI) and bl

296 s, ST1193-H64 isolates were more extensively multidrug resistant, whereas their virulence genotypes w

297 Candida auris is a multidrug-resistant yeast associated with hospital outbr

298 The multidrug-resistant yeast pathogen Candida auris continu

299 Candida auris is an emerging multidrug-resistant yeast that has been systematically i

300 Candida auris is a multidrug-resistant yeast which has emerged in health ca